NASDAQ:IPA ImmunoPrecise Antibodies (IPA) Stock Price, News & Analysis $1.64 -0.02 (-1.20%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.69 +0.05 (+3.05%) As of 07:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ImmunoPrecise Antibodies Stock (NASDAQ:IPA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get IPA alerts:Sign Up Key Stats Today's Range$1.52▼$1.6450-Day Range$0.53▼$2.3152-Week Range$0.27▼$2.41Volume1.01 million shsAverage Volume2.19 million shsMarket Capitalization$75.69 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingBuy Company Overview ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada. Read More ImmunoPrecise Antibodies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreIPA MarketRank™: ImmunoPrecise Antibodies scored higher than 40% of companies evaluated by MarketBeat, and ranked 666th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingImmunoPrecise Antibodies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmunoPrecise Antibodies has received no research coverage in the past 90 days.Read more about ImmunoPrecise Antibodies' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ImmunoPrecise Antibodies are expected to grow in the coming year, from ($0.27) to ($0.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ImmunoPrecise Antibodies is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ImmunoPrecise Antibodies is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunoPrecise Antibodies has a P/B Ratio of 4.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ImmunoPrecise Antibodies' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.25% of the float of ImmunoPrecise Antibodies has been sold short.Short Interest Ratio / Days to CoverImmunoPrecise Antibodies has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ImmunoPrecise Antibodies has recently increased by 114.54%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmunoPrecise Antibodies does not currently pay a dividend.Dividend GrowthImmunoPrecise Antibodies does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.25% of the float of ImmunoPrecise Antibodies has been sold short.Short Interest Ratio / Days to CoverImmunoPrecise Antibodies has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ImmunoPrecise Antibodies has recently increased by 114.54%, indicating that investor sentiment is decreasing significantly. News and Social Media1.8 / 5News Sentiment-0.78 News SentimentImmunoPrecise Antibodies has a news sentiment score of -0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for ImmunoPrecise Antibodies this week, compared to 1 article on an average week.Search Interest13 people have searched for IPA on MarketBeat in the last 30 days. This is an increase of 30% compared to the previous 30 days.MarketBeat Follows7 people have added ImmunoPrecise Antibodies to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ImmunoPrecise Antibodies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.83% of the stock of ImmunoPrecise Antibodies is held by insiders.Percentage Held by InstitutionsOnly 6.70% of the stock of ImmunoPrecise Antibodies is held by institutions.Read more about ImmunoPrecise Antibodies' insider trading history. Receive IPA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmunoPrecise Antibodies and its competitors with MarketBeat's FREE daily newsletter. Email Address IPA Stock News HeadlinesHC Wainwright Issues Negative Outlook for IPA EarningsAugust 2 at 3:41 AM | americanbankingnews.comIPA interactive stock chart | ImmunoPrecise Antibodies Ltd. stock - Yahoo FinanceJuly 29, 2025 | nz.finance.yahoo.comMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alternative Assets reveals 3 urgent moves to protect your portfolio, plus the #1 asset class thriving during crises (hint: it’s not stocks or bonds).August 4 at 2:00 AM | American Alternative (Ad)ImmunoPrecise Antibodies Reports Record Revenue and GrowthJuly 29, 2025 | tipranks.comImmunoPrecise Antibodies Reports Record Fiscal Year 2025 ResultsJuly 29, 2025 | tipranks.comImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDAJuly 29, 2025 | businesswire.comImmunoPrecise Unveils Breakthrough in Predicting Drug Antibody RisksJuly 24, 2025 | tipranks.comImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the ClinicJuly 24, 2025 | businesswire.comSee More Headlines IPA Stock Analysis - Frequently Asked Questions How have IPA shares performed this year? ImmunoPrecise Antibodies' stock was trading at $0.4117 on January 1st, 2025. Since then, IPA shares have increased by 298.3% and is now trading at $1.64. How were ImmunoPrecise Antibodies' earnings last quarter? ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) issued its earnings results on Tuesday, July, 29th. The company reported ($0.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by $0.02. The firm earned $5.06 million during the quarter, compared to analysts' expectations of $7.89 million. ImmunoPrecise Antibodies had a negative net margin of 122.10% and a negative trailing twelve-month return on equity of 40.62%. Read the conference call transcript. Who are ImmunoPrecise Antibodies' major shareholders? ImmunoPrecise Antibodies' top institutional investors include Ingalls & Snyder LLC (6.07%) and Baader Bank Aktiengesellschaft (0.06%). How do I buy shares of ImmunoPrecise Antibodies? Shares of IPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ImmunoPrecise Antibodies own? Based on aggregate information from My MarketBeat watchlists, some other companies that ImmunoPrecise Antibodies investors own include NVIDIA (NVDA), Arista Networks (ANET), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), GE Aerospace (GE) and ServiceNow (NOW). Company Calendar Last Earnings7/29/2025Today8/04/2025Next Earnings (Estimated)9/15/2025Fiscal Year End4/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MEDICAL INFO SYS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IPA CIK1715925 Webwww.immunoprecise.com Phone250-483-0308FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Price Target for ImmunoPrecise Antibodies$4.00 High Price Target$5.00 Low Price Target$3.00 Potential Upside/Downside+143.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.69 million Net Margins-122.10% Pretax Margin-139.75% Return on Equity-40.62% Return on Assets-22.19% Debt Debt-to-Equity Ratio0.49 Current Ratio2.08 Quick Ratio1.85 Sales & Book Value Annual Sales$17.59 million Price / Sales4.30 Cash FlowN/A Price / Cash FlowN/A Book Value$0.37 per share Price / Book4.43Miscellaneous Outstanding Shares46,150,000Free Float43,002,000Market Cap$75.69 million OptionableNot Optionable Beta0.49 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:IPA) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredWall Street Laughed. Now They're Buying.For six months, I’ve been pounding the table on a major gold miner—while Twitter pundits laughed. But now, the...Golden Portfolio | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Create New Advertiser | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoPrecise Antibodies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunoPrecise Antibodies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.